The mixed lineage leukaemia gene, MLL (also called HRX, ALL-1) in acute leukaemia is fused to at least 16 identified partner genes that display diverse structural and biochemical properties. Using GST pull down and the yeast two hybrid system, we show that two different MLL fusion partners with SH3 domains, EEN and Abi-1, interact with dynamin and synaptojanin, both of which are involved in endocytosis. Synaptojanin, a member of the inositol phosphatase family that has recently been shown to regulate cell proliferation and survival, is also known to bind to Eps15, the mouse homologue of AF1p, another fusion partner of MLL. Expression studies show that synaptojanin is strongly expressed in bone marrow and immature leukaemic cell lines, very weakly in peripheral blood leukocytes and absent in Raji, a mature B cell line. We found that the SH3 domains of EEN and Abi-1 interact with different proline-rich domains of synaptojanin while the EH domains of Eps15 interact with the NPF motifs of synaptojanin. In vitro competitive binding assays demonstrate that EEN displays stronger binding affinity than Abi-1 and may compete with it for synaptojanin. These findings suggest a potential link between MLL fusion-mediated leukaemogenesis and the inositol-signalling pathway. Leukemia (2000) 14, 594-601.
Introduction
The mixed lineage leukaemia gene, MLL (also known as HRX, ALL-1 and HTRX) [1] [2] [3] [4] on chromosome band 11q23 is unique for its ability to form fusion genes and to undergo self-fusion as well as specific deletion in leukaemic cells. 5 MLL contains several functional motifs, including leukaemia associated protein/plant homeodomain fingers, 6, 7 AT-hook DNA binding motif, a DNA methyltransferase homology region and the SET domain. 3, 4 The functional importance of these motifs in vertebrate homologues of TRX proteins has been supported by the finding of an extraordinary degree of sequence conservation in distant higher vertebrates. 8 Gene knockout studies in mice indicate that MLL is required in the yolk sac for the normal development of myeloid/macrophage progenitors 9 and, like TRX gene in Drosophilia, functions as a regulator of HOX gene expression. 10 At least 16 MLL fusion genes, which arise as a result of chromosomal translocations, have been identified in a variety of leukaemias including acute lymphoid leukaemia (ALL), acute myeloid leukaemia (AML), mixed lineage leukaemia, chemotherapy-related AML and myelodysplastic syndrome. 5, 11 The pathogenic significance of fusion genes has been shown by three separate sources of evidence. Firstly, analysis of MLL fusion transcripts revealed that 5Ј MLL sequences, including those encoding the AT hook and methyltransferase motifs, are always joined in-frame to 3Ј sequences of the respective partner gene (reviewed in Ref. leukaemic transformation of myelomonocytic progenitors followed retroviral-mediated gene transfer of MLL/ENL into enriched myeloid progenitor cells. 12 Deletion of either the AT hook/methyltransferase domain of MLL or the C-terminal helical structure of ENL in MLL/ENL impaired its oncogenic potential. 13 Thirdly, introduction of MLL/AF9 into mouse embryonic stem cells leads to the development of leukaemia. 14 Given the diverse nature of the known and predicted protein structures encoded by the partner genes, it is unlikely that one common mechanism explains the functional contribution of the partner genes to leukaemogenesis. Partners found fused to MLL include nuclear proteins, which have a direct impact on transcription, ie an RNA polymerase II elongation factor (ELL), [15] [16] [17] transcriptional coactivators (CREB binding protein and p300), 18, 19 putative transcription factors (AF4, AF6q21, AF9, AF10, AF17, ENL and AFX) [20] [21] [22] [23] [24] [25] [26] as well as cytoplasmic proteins with homology to myosin (AF6 and AF1p) 27, 28 and those characterized by the presence of SH3 domains (EEN and Abi-1). 29, 30 EEN was cloned as a fusion partner of MLL from a case of infant acute myeloid leukaemia. 29 It encodes a 46 kDa protein and contains an SH3 domain in the C-terminal region. Using EEN-related expression sequence tagged (EST) clones to screen a human fetal cDNA library or other approaches, we and others have identified two EEN family members, EEN-B1 and EEN-B2 (named for their preferential expression in brain) in human 31 (So et al, unpublished data) , mouse 32 and rat. 33 EEN family members encode predicted proteins with highly conserved SH3 domains that show the highest homology to the SH3 domain found in Grb-2/Sem-5, a member of the family of adaptor proteins conserved from fruitfly to mammals. [34] [35] [36] These adaptor proteins, characterized by an SH2-SH3-SH2 structure, couple receptor tyrosine kinases to the Ras signalling pathway and participate in both normal and pathogenic pathways. They bind to the activated receptor via their SH2 domains and recruit downstream effectors, such as guanine nucleotide exchange factor, through the interaction of their SH3 domains with proline-rich peptide sequences of the target proteins (reviewed in Ref. 37) . Mutations in the SH3 domain of the Grb2/Sem-5 protein abolish binding to downstream effectors, and result in loss of function. 34, 35 Recently, the SH3 domains of Grb-2 have also been found to associate with two major brain proteins, dynamin and synaptojanin. [38] [39] [40] Interactions between the SH3 domain of Grb2 and the proline-rich tail of dynamin 41, 42 stimulate the GTPase activity of dynamin, leading to conformational changes of the dynamin rings and vesicle fission. Mutation of the dynamin gene in Drosophila impaired the recycling and endocytosis of synaptic vesicle membrane. 43, 44 These data suggest that dynamin is required for endocytosis in presynaptic vesicles.
Synaptojanin is an inositol-5-phosphatase found in presynaptic terminals 40 and also in non-neural cells. Two isoforms of synaptojanin, 170 kDa and 145 kDa, exist due to alternative splicing. Synaptojanin-170 differs from synaptojanin-145 in having an additional 300 amino acid carboxyl terminal tail, which is proline rich and contains three NPF motifs. Evidence indicates that synaptojanin-145, which is very abundant in nerve terminals, has a key role in clathrin-mediated endocytosis of synaptic vesicles, whilst synaptojanin-170 which is more abundant than synaptojanin-145 in developing brain and non-neuronal cells may be involved in a housekeeping mechanism of endocytosis and possibly additional functions. 40, 45 Based on the high sequence homology between the SH3 domains of EEN and Grb-2 proteins, we speculated that the SH3 domains of EEN family members would interact with synaptojanin and dynamin. We demonstrated this interaction and further showed that Abi-1, another MLL fusion partner, also bound to the same binding proteins as EEN via its SH3 domain. Recently, synaptojanin-170 has been found to interact and co-localize with Eps15, 46 the mouse homologue of AF1p, also a fusion partner of MLL. 28 These findings suggest that synaptojanin is a common binding target for three different MLL fusion partners involved in leukaemia-associated translocations.
Materials and methods

Gene expression studies by Northern hybridization
Poly(A)+ selected RNA human multiple tissue Northern blots (Clontech, Palo Alto, CA, USA) were hybridized with cDNA probes derived from specific coding sequence or the 3Ј untranslated region of the genes. Probes used for hybridization were: (1) 1.6 kb PstI fragment spanning part of the coding and 3Ј untranslated region of EEN (GenBank accession No. U65999); (2) 2.8 kb probe covering the coding and part of the 3Ј untranslated region of EEN-B1 (GenBank accession No. AF036268); (3) 400 bp probe derived from the 3Ј untranslated region of EEN-B2 (GenBank accession No. AF036269); (4) 900 bp EcoRV fragment covering the 5Ј coding region of human Abi-1 (e3B1) (GenBank accession No. AF006516); and (5) 1.6 kb SacI cDNA fragment derived from rat synaptojanin (GenBank accession No. U45479), which is highly conserved in the human counterpart (over 85% identity). Hybridization was performed under standard high stringency conditions. 47 
Production of GST fusion protein and in vitro synthesized proteins
Full-length and different coding regions of EEN family members (EEN, EEN-B1 and EEN-B2), Abi-1 (GenBank accession U17698), Grb2 (GenBank accession S26050), and the SH3 domains of PLC␥ (GenBank accession M34667, 793-851 aa) and rasGAP (GenBank accession M23379, 274-347 aa) were amplified by PCR on appropriate cDNA templates and cloned in frame into pGEX vectors that expressed recombinant GST fusion proteins. Constructs were verified by DNA sequencing prior to the expression of the GST fusion protein in the host strain DH5␣ upon IPTG induction using standard methods. 47 Human dynamin I and rat synaptojanin I (145 kDa isoform) were kind gifts from P De Camilli (Yale University, New Haven, CT, USA). The C-terminal region of synaptojanin-1 (170 kDa isoform), covering the three NPF motifs, was amplified by RT-PCR on human bone marrow cDNA and cloned into pGEM-t (Promega, Madison, WI, USA). Following column purification (Qiagen, Hilden, Germany), 1 g of each plasmid DNA was expressed using the TNT coupled reticulocyte lysate Leukemia system (Promega) according to the manufacturer's instructions. All protein products were analyzed on an SDS/12% polyacrylamide gel and subjected to autoradiography, or immunoblotting using anti-GST antibody.
GST pull-downs
One g aliquots of GST fusion proteins were pre-incubated with glutathione sepharose beads (Amersham Pharmacia Biotech, Buckinghamshire, UK) in NETN buffer (0.5% NP-40, 20 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA) for 60 min at 4°C. 35 S-labelled in vitro synthesized proteins, including dynamin I, synaptojanin-I (145 kDa isoform) and the NPF motifs of synaptojanin I (170 kDa isoform), were added to the GST sepharose bead and incubated at 4°C for 90 min. The beads were washed five times in buffer H (20 mM Hepes pH 7.7, 50 mM KCl, 20% glycerol, 0.1% NP40 and 0.007% ␤-mercaptoethanol). Bound proteins were eluted by boiling in SDS-PAGE loading buffer, resolved by electrophoresis and visualized by autoradiography.
Competitive binding assays
One g aliquots of GST fusion proteins were pre-incubated with glutathionine sepharose beads in NETN buffer for 60 min at 4°C and used in the following: (1) Peptide competitive binding assays: 35 S-labelled in vitro synthesized synaptojanin (145 kDa isoform) was added, together with the synaptojaninderived peptides (S1-S5), to the beads at a final concentration of 5 M, 25 M or 200 M. S1-S5 peptides (S1, SAPSLPIRP; S2, EPKRPPPPRPV; S3, ARPAPPQRP; S4, ARPTIPARA; S5, TPPLPPPRS) (Genosys, Cambridge, UK) were derived from the predicted amino acid sequence of synaptojanin, and each peptide contained an SH3 domain binding consensus sequence (class I: RXqPXqP, or class II: qPXqPXR, where q may be any hydrophobic amino acid and X is any amino acid), 48, 49 which is conserved in both human and rat homologs. S4-1K (ARPTIKARA) and S5-1K (TPPLPKPRS) were mutant forms of S4 and S5 with the consensus proline (P) residue converted to lysine (K). (2) EEN/Abi-1 competitive assay: 35 S-labelled in vitro synthesized synaptojanin was added together with 1, 5, 25 or 50 g EEN-SH3 or Abi-SH3 recombinant protein to the beads. These proteins were identical to those used for GST pull-down except that the GST portions of the fusion proteins had been removed by factor Xa (Amersham Pharmacia Biotech) digestion according to the manufacturer's instruction. After 90 min incubation at 4°C, the beads were washed five times in buffer H. Bound proteins were eluted and visualized by autoradiography as described. All competitive binding assays were repeated at least twice to confirm the results.
Yeast two hybrid studies
Gal4-based MATCHMAKER Two-Hybrid System from Clontech was used to test for the in vivo interaction between EEN/Abi-1 and synaptojanin. Briefly, SH3 domains of EEN, Abi-1 and rasGAPase were cloned in-frame with Gal4 activation domain (ad, 768-881 aa of the yeast GAL4 protein) in pACT2 vector while the proline-rich domain (PRD) of synaptojanin (GenBank accession No. U45479, 1010 aa to the stop codon) was cloned in-frame with Gal4 DNA-binding domain (bd, 1-147 aa of the yeast GAL4 protein) in pAS2-1 vector. Constructs of Gal4ad and Gal4bd were then co-transformed into yeast reporter strain Saccharomyces cerevisiae SFY-562 expressing the Escherichia coli lacZ gene driven by the intact Gal4-responsive GAL1 promoter using standard LiAc transformation protocols described by the manufacturer. The transformants were plated on to synthetic dropout medium without leucine and tryptophan (SD/-Leu/-Trp) for the positive selection of transformants with both Gal4bd (Trp1 + ) and Gal4ad (Leu2 + ) constructs. A qualitative colony-lift filter assay was performed using 5-bromo-4chloro-3indolyl-␤-D-galactopyranoside (X-gal) as substrate. Briefly, yeast transformants were transferred to Whatman No. 1 filter paper (Maidstone, UK), permeabilized by submerging in liquid nitrogen, allowed to thaw at room temperature and placed on to another filter presoaked in Z-buffer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 100 mM KCl, 1 mM MgSO 4 and 50 mM ␤-mercaptoethanol) containing 0.5 mg/ml X-gal. Incubation for colour development took place at 30°C for 6 h. As positive controls, fulllength cDNAs of human Int-6 protein 50 were cloned in-frame with Gal4ad while human T cell leukaemia virus type I (HTLV-1) Tax protein 51 was cloned in-frame with Gal4ad and Gal4bd for the tests. Each set of experiments was repeated at least twice in order to confirm the results.
Results
Expression studies of EEN gene family
The levels of expression of EEN gene family were examined in Northern blots of polyA+ RNA from different human tissues (Figure 1) . EEN is expressed ubiquitously in all adult and fetal
Figure 1
Northern blot analysis of EEN family and synaptojanin. The multiple tissue blots were hybridized with cDNA probes derived from (a) EEN, (b) EEN-B1, (c) EEN-B2, (d) Abi-1 , or (e) synaptojanin. The blots were then stripped and rehybridized with an actin probe to assess the RNA quality.
tissues tested while EEN-B1 and -B2 exhibited a high degree of spatial and temporal expression specificity. The expression of EEN-B1 in adult tissues appears to be specific for the brain whilst EEN-B2 is expressed not only in adult brain but also in testis (highest level) and thymus. In fetal tissues, expression of EEN-B1 and -B2 can also be found in the lung and kidney, but not in the liver, where fetal haemopoiesis takes place.
EEN family and Abi-1 bind dynamin and synaptojanin via their SH3 domains
Based on the expression pattern of the EEN family and the sequence homology to the C-terminal SH3 domain of GrB2 protein, known to bind to synaptic proteins of mouse brain extract including dynamin and synaptojanin, 38, 39 we investigated the possible interaction between the EEN family with dynamin-I and synaptojanin-I (145 kDa isoform). Each GST fusion protein containing the full sequence of EEN family members (EEN, EEN-B1 and EEN-B2) could bind to 35 Slabelled dynamin and synaptojanin ( Figure 2 ). Further deletion mapping showed that precipitations of dynamin and synpatojanin were mediated by the SH3 domain of the EEN family. Very faint bands of dynamin and synaptojanin could also be seen using GST-␣-helix motif fusion proteins ( Figure 2 ) which were likely to represent non-specific binding.
Another SH3 domain-containing protein, Abi-1, was recently identified as being fused with MLL in human leukaemia. 30 Abi-1, like EEN, is ubiquitously expressed in both adult and fetal tissues (Figure 1 ). We also found that Abi-1 could bind dynamin and synaptojanin via its SH3 domain (Figure 2 ). To demonstrate that these SH3 domain-mediated GST pull-down using various SH3 domain-containing GST fusion proteins against 35 S-labelled dynamin or synaptojanin. Full-length or various parts of SH3 domain-containing proteins expressed as GST fusion proteins were immobilized on glutathione agarose to precipitate 35 S-labelled (a) dynamin, (b) synaptojanin-145, or (c) C-terminal of synaptojanin-170 that contains the NPF domains. The input and empty GST control are indicated.
bindings were specific, SH3 domains of various signal transduction molecules were tested for binding to dynamin and synaptojanin. The SH3 domains of Grb2 and PLC␥, but not rasGAP, could bind to dynamin and synaptojanin ( Figure 2 ) which was consistent with the previous finding on dynamin. 52 Thus these results of in vitro interactions were specific rather than due to non-specific binding of the SH3 domain.
To demonstrate the in vivo interaction between EEN/Abi-1 and synaptojanin, SH3 domains of EEN/Abi-1 and the prolinerich domain (PRD) of synaptojanin were cloned in-frame into Gal4ad and Gal4bd, respectively, for yeast two hybrid studies. HTLV-1 Tax protein that can self-associate to form strong homodimer 50 and interact with human Int-6 protein 51 was used as positive control for the assay. In the qualitative colony-lift filter assay, yeast transformants with either EEN/synaptojanin or Abi-1/synaptojanin turned blue within 6 h after the assay was started although the colour of EEN/synaptojanin transformed yeast were deeper (Figure 3 ). In the positive controls, yeast transformants with Gal4bd-Tax and Gal4ad-Tax turned deep blue while transformants with Gal4bd-Tax and Gal4ad-Int-6 became pale blue that was comparable to that of Abi-1/synaptojanin transformants. Controls either co-transformed with Gal4bd-PRD and empty Gal4ad or Gal4bd-PRD and Gal4ad-rasGAP-SH3 were negative for X-gal staining (Figure 3) . Negative results were also obtained when yeast co-transformed with empty Gal4ad and Gal4bd-EEN or Gal4db-Abi-1 (data not shown). These data confirmed the in vivo interaction between EEN/Abi-1 and synaptojanin.
Expression of synaptojanin in haemopoietic cells
Synaptojanin has been widely studied for its role as an endocytic molecule in recycling of synaptic vesicles. Both isoforms (145 kDa and 170 kDa) are widely expressed in various nonneuronal tissues, although the 145 kDa isoform is highly enriched in the brain. 45 To investigate the possible functions of synaptojanin in haemopoiesis, we studied its expression in various stages of haemopoietic cells and immune tissues (Figure 1e) . Synaptojanin was expressed in bone marrow and Colony-lift filter assay for the yeast two hybrid studies. X-gal staining results of yeast transformants with (a) Gal4bd-Tax and Gal4ad-Int-6; (b) Gal4bd-Tax and Gal4ad-Tax; (c) Gal4bd-PRD and Gal4ad-EEN; (d) Gal4bd-PRD and Gal4ad-Abi-1; (e) Gal4bd-PRD and empty Gal4ad; and (f) Gal4bd-PRD and Gal4ad-rasGAP-SH3 after incubation at 30°C for 6 h.
immature haemopoietic pregenitor cell lines including HL-60 (promyelocyte), K-562 (early erythrocyte) and Molt-4 (immature T cell), but not in Raji (mature B cell); it was very weakly expressed in peripheral blood leukocytes (weak signal could be seen under long exposure; data not shown). These results suggest that the expression of synaptojanin is differen- tially regulated during haemopoietic development and that its expression in early progenitor cells may be functionally important.
Mapping of EEN and Abi-1 binding sites on synaptojanin
It is notable that Eps15, the mouse homolog of AF1p, a fusion partner of MLL in t(1; 11)(p321 q23) 28 has recently been shown to bind to the NPF motifs of synaptojanin-170, 46 which is generated by alternative use of a 3Ј exon containing a stop codon. 40 We then investigated whether EEN and Abi-1 share the same interacting motifs as Eps15 on synaptojanin. There was no binding of any EEN-SH3 or Abi-SH3 proteins to the in vitro synthesized C-terminal tail of synaptojanin-170, which contains the NPF motifs and a short stretch of proline-rich sequences (Figure 2) . In order to map the binding sites of the EEN family and Abi-1 on synaptojanin, we performed peptide competitive binding assays using synthetic peptides that contain consensus SH3-domain binding sequences from synaptojanin (Figure 4) . The binding of EEN-SH3 domain to synaptojanin was very specific and only S2 peptide could abolish its binding. Similar binding results were obtained for the SH3 domains of EEN-B1 and -B2. However, both S4 and S5, but not S2, could inhibit the binding of Abi-1 to synaptojanin, which suggests that the EEN family and Abi-1 have different binding sites on synaptojanin. The specificity of these bindings was confirmed using mutant peptides derived from S4 and S5. S4-1K and S5-1K, which had a single amino acid substitution in which one of the consensus proline (P) residues was converted to lysine (K), did not inhibit the binding of Abi-SH3 domain to synaptojanin.
EEN compete with Abi-1 for synaptojanin
The binding relationship between EEN and Abi-1 on synaptojanin was studied by in vitro competitive binding assays using GST-EEN-SH3 and Abi-SH3 or vice versa. The binding of GST-EEN-SH3 to synaptojanin was inhibited only by EEN-SH3 itself, not by Abi-SH3 or rasGAP-SH3 ( Figure 5 ). On the other hand, GST-Abi-SH3 binding could be abolished by either Abi-SH3 or EEN-SH3 but not by rasGAP-SH3 protein. As little as 5 g of EEN-SH3 protein could inhibit binding of Abi-1 to synaptojanin. Complete inhibition was achieved using 25 g of EEN-SH3 whereas 50 g of Abi-SH3 protein was required for a complete abolition of GST-Abi-SH3 binding ( Figure 5 ).
Discussion
Characterization of genes located at chromosomal translocation breakpoints has facilitated our understanding of the pathogenesis of leukaemia mediated by gene fusions. EEN was first identified as a fusion gene to MLL in a case of infant acute myeloid leukaemia. 29 Although three EEN family members show a very high degree of sequence and structural homology to each other 31 (So et al, unpublished data) , expression studies show that EEN is the only family member expressed in haemopoietic tissues, including bone marrow and fetal liver. This indicates that EEN may have more general and/or different functions from those of EEN-B1 and -B2 in haemopoietic cells.
We have identified two EEN binding proteins, dynamin and synaptojanin. Using GST pull-downs, we showed that the SH3 domains of the EEN family interact with the proline-rich regions of dynamin and synaptojanin. Our results are consistent with the recent finding of a yeast two hybrid study showing that the rat homologues of the EEN family, SH3p8, SH3p4 and SH3p13, are the binding partners for synaptojanin and dynamin in the rat brain. 33 Using a yeast two hybrid system we have also demonstrated that EEN and Abi-1, another SH3 domain containing a MLL fusion partner, 30 interact with the proline-rich domain of synaptojanin via its SH3 domain. Interestingly, synaptojanin was previously found to bind to the EH domains of Eps15, 46 another MLL fusion partner involved in leukaemia. 28 Although EEN, Abi-1 and Eps15 interact with the same protein, Eps15 binds to the NPF motifs while EEN and Abi-1 bind to the PRD of synaptojanin. Abi-1 binds to consensus class II SH3 binding sites (qPXqPXR, S4 and S5) whereas EEN preferentially binds to the class I-like SH3 binding site (RXqPXqP, S2). These bindings are specific, since competitor peptides mutated in the consensus sequences (S4-1K, S5-1K) largely reduced their ability to inhibit the Abi-1 binding to synaptojanin. EEN and Abi-1 are ubiquituously-expressed proteins present in haemopoietic cells. We show that EEN exhibits higher binding affinity and can compete with Abi-1 for synaptojanin. This suggests that these MLL fusion partners may interfere with each other in binding to synaptojanin. Identification of the same binding protein shared by different MLL fusion partners in leukaemia leads to speculation that synaptojanin may play an important regulatory role in haemopoiesis.
Both synaptojanin and dynamin have been extensively studied for their roles in clathrin-mediated endocytosis, which serve diverse functions in different cell types including synaptic vesicle recycling in neurons, and internalization of receptor-bound hormones and growth factors in proliferating cells. 42, 53 It has been proposed that cancer may arise in cells with impaired endocytosis as a result of enhanced cell prolifereation due to prolonging signalling by growth factors. 54 This is consistent with the recent finding that cells expressing dominant negative dynamin mutant resulting in impaired endocytosis exhibited an enhanced proliferative response to epidermal growth factor (EGF). 55 It is possible that disturbance of the normal interactions between MLL fusion partners and these endocytic proteins, synaptojanin and dynamin, may deregulate endocytic processes involved in cell proliferation and/or survival, and this at least partially contributes to the leukaemogenic effects of the translocation products.
A second mechanism that may link synaptojanin to MLLLeukemia mediated leukaemogenesis is its property as a member of the type II inositol-5-phosphatase family which also includes SH2-containing inositol-5-phosphatase (SHIP). In general, both synaptojanin and SHIP proteins have a large N-terminal and a central 5Ј-phosphatase domain that show high homology to each other, preceding a C-terminal proline-rich tail which can specifically interact with the SH3 domains of Grb2. 38, 40, 56, 57 Significantly, both proteins have the 5Ј-phosphatase activity on phosphatidylinositol-3,4,5-trisphophate (PtdIns(3,4,5)P 3 ) [56] [57] [58] which is the primary in vivo product of phosphatidylinositol 3-kinase (PI-3 kinase). PtdIns(3,4,5)P 3 is an important second messenger regulating cell proliferation and survival, 59 that can activate both protein kinase B (PKB)-and p70 s6k -mediated signaling. 60 Several pieces of evidence currently implicate the involvement of inositol phosphatases in oncogenesis. Firstly, genetargeted disruption of SHIP leads to haemopoietic perturbations, with increased numbers of granulocyte-macrophage progenitors in the bone marrow and spleen, probably resulting from hyper-responsiveness to stimulation by various cytokines, eg MCSF, GMCSF, IL-3 and Steel factor. 61 Secondly, over-expression of SHIP has been shown to reduce the size of the macrophage colony-stimulating factor receptor-or IL-3-stimulated FDC-P1 cell colonies in soft agar 57 and increase the rate of apoptosis of DA-ER cells. 62 The apoptotic effect of SHIP has been suggested to be due to its ability to counteract the effect of PI-3 kinase, 62 which prevents apoptosis in certain cell types. 63 Thirdly, mutation-mapping analysis has linked the tumour suppressor property of PTEN, to its inositol phosphatase activity. 64, 65 Over-expression of wild-type PTEN, but not PTEN-G129E or PTEN-C124S mutants with defects in phosphoinositide phosphatase activity, has been shown to reduce the level of PtdIns(3,4,5)P 3 and result in growth suppression. [66] [67] [68] These data suggest that the physiological function of PTEN as a tumour suppressor gene is to antagonize signalling downstream of PI-3K by dephosphorylating PtdIns(3,4,5)P 3 , 68 which is also the target substrate for SHIP and synaptojanin.
Although the physiological functions of synaptojanin in haemopoietic cells are largely unknown, its ability to dephosphorylate the products of PI-3K and its specific interaction with various MLL fusion partners suggest that it plays an important role in MLL-mediated leukaemogenesis. It is possible that fusion of EEN, Abi-1 or Eps15 to MLL disrupts the normal interactions between synaptojanin and these fusion partners, which is necessary to localise synaptojanin to appropriate reaction sites and/or stimulate its activity. This is consistent with the findings that MLL-Eps15 69 and MLL-EEN fusion proteins (So et al, unpublished data) are translocated into specific compartments in the nucleus while the wild-type Eps15, EEN and synaptojanin are found mainly in cytoplasm. Interaction between synaptojanin and Abi-1 may also interfere with the growth suppressive property of Abi-1. It has been established that over-expression of Abi-1 markedly reduces the transformation activity of Abelson leukaemia virus expressing the full-length p160 v-abl kinase in NIH3T3 cells 70 and in NIH/EGFR fibroblasts. 71 Finally, it is notable that AF-X, another MLL fusion partner involved in human leukaemia, 26 is also down-regulated by PI-3K via activating protein kinase B (PKB). 72 Phosphorylation of AF-X by PKB alters its subcellular localization and inhibits its transcriptional activity. These findings strengthen further a link between inositol signalling pathway and MLL fusion-mediated leukaemogenesis. Obviously, future studies exploring the functions of synaptojanin and inositol signalling pathways in the haemopoietic system will reveal new insights into their roles in normal haemopoiesis and leukaemogenesis.
Note
Nucleotide sequences of EEN-B1 and EEN-B2 have been deposited in GenBank with accession numbers AF036268 and AF036269, respectively.
